BridgeBio Pharma, Inc. (BBIO)
75.03
+0.96
(+1.30%)
USD |
NASDAQ |
Dec 12, 15:54
BridgeBio Pharma Research and Development Expense (Quarterly): 112.87M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Pfizer Inc. | 2.492B |
| Alnylam Pharmaceuticals, Inc. | 358.81M |
| Supernus Pharmaceuticals, Inc. | 28.87M |
| Ionis Pharmaceuticals, Inc. | 217.13M |
| Regeneron Pharmaceuticals, Inc. | 1.338B |